Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on September 9, 2026 reporting Item 7.01 (Regulation FD Disclosure). XP-8121 Program Overview webinar scheduled for September 9, 2026.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- XP-8121 Program Overview webinar scheduled for September 9, 2026
- Investor presentation and accompanying press release provide program updates, accessible through Exhibits 99.1 and 99.2
- Disclosure signals an investor-focused update on XP-8121 development and potential strategic relevance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.